Suneil Kalia, MD, PhD, FRCS(C), is a scientist at Krembil Research Institute and Assistant Professor in Neurosurgery at the University of Toronto. His research laboratory focuses on understanding molecular mechanisms of protein homeostasis in neurodegeneration and on establishing model systems to study protein function in Parkinson’s disease (PD). As a neurosurgeon his clinical focus is on the surgical management of movement disorders, particularly PD.

Dr. Kalia received his BSc at McGill University and his MD and PhD degrees from the University of Toronto. In 2006 he entered the neurosurgery residency program at University of Toronto, during which he completed a postdoctoral research fellowship at the Massachusetts General Hospital Institute for Neurodegenerative Disease at Harvard University. After obtaining his FRCS(C) in neurosurgery, he undertook subspecialty training in stereotactic and functional neurosurgery at the Toronto Western Hospital.

His team is actively working on developing novel biological therapies that are designed to slow or halt the progression of neurodegeneration in PD.
Parkinson’s disease (PD) is a disabling movement disorder that affects between 1-3% of the Canadian population over the age of 65. Poor handling and elimination of misfolded proteins has been identified as central in the molecular pathogenesis of PD. A special class of proteins within the cell called “chaperones” is responsible for refolding misfolded or damaged proteins. If the chaperone system cannot adequately deal with these misfolded proteins, they are targeted to specialized disposal systems in the cell including the ubiquitin-proteasome system and the autophagy-lysosomal system. Together these pathways are critical to maintain protein quality control within a cell. If they are dysfunctional or overwhelmed then neurodegeneration ensues.
 
Our current work is aimed at:
1)      Understanding how chaperone molecules fail to maintain adequate protein quality control in PD and other neurodegenerative disorders;
2)      Dissecting molecular pathways that contribute to aberrant protein disposal via the proteasome and lysosomal systems in PD; and,
3)      Developing innovative methods to target and regulate these protein quality control pathways in PD and other neurodegenerative disorders.
 
Our ultimate goal is to find ways to mitigate the loss of neurons in the brain to be able to slow or even halt the progression of PD and other neurodegenerative disorders.
J Korean Neurosurg Soc. 2019 May;62(3):353-360
Lee EJ, Kalia SK, Hong SH
J Neurosurg. 2019 Feb 22;:1-9
Lee DJ, Milosevic L, Gramer R, Sasikumar S, Al-Ozzi TM, De Vloo P, Dallapiazza RF, Elias GJB, Cohn M, Kalia SK, Hutchison WD, Fasano A, Lozano AM
Mov Disord. 2019 Feb 15;:
De Vloo P, Reddy GD, Rowland N, Sammartino F, Llinas M, Paul D, Murray BJ, Lang AE, Fasano A, Munhoz RP, Kalia SK
J Neurosci. 2019 Jan 29;:
Gondard E, Teves L, Wang L, McKinnon C, Hamani C, Kalia SK, Carlen PL, Tymianski M, Lozano AM
Book. 2018 12 21
Stoker TB, Greenland JC
Ann Clin Transl Neurol. 2019 Jan;6(1):174-185
McKinnon C, Gros P, Lee DJ, Hamani C, Lozano AM, Kalia LV, Kalia SK
Mov Disord. 2019 Jan 11;:
De Vloo P, Lee DJ, Dallapiazza RF, Rohani M, Fasano A, Munhoz RP, Ibrahim GM, Hodaie M, Lozano AM, Kalia SK
J Magn Reson Imaging. 2018 Dec 15;:
Hancu I, Boutet A, Fiveland E, Ranjan M, Prusik J, Dimarzio M, Rashid T, Ashe J, Xu D, Kalia SK, Hodaie M, Fasano A, Kucharczyk W, Pilitsis J, Lozano A, Madhavan R
Mov Disord. 2018 Nov 13;:
Harmsen IE, Lee DJ, Dallapiazza RF, De Vloo P, Chen R, Fasano A, Kalia SK, Hodaie M, Lozano AM
Mov Disord. 2018 Nov 13;:
Picillo M, Lizarraga KJ, Friesen EL, Chau H, Zhang M, Sato C, Rooke G, Munhoz RP, Rogaeva E, Fraser PE, Kalia SK, Kalia LV

Pages


Assistant Professor University of Toronto